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Introduction: Carnosine (β-alanyl-L-histidine) is a naturally occurring dipeptide, widely 
and abundantly distributed in the muscle and nervous tissues of animal species. 
Carnosine contains several beneficial biological properties, such as antiglycating and 
antioxidant activities. It also contains antineoplastic effects in human cell culture as well 
as in animal experiments; however, the clear molecular basis of this activity has not been 
known yet. In the present study, in order to further examine structural basis of Carnosine 
for the anticancer activity, some linear and cyclic Carnosine peptide analogues were 
synthesized and their cytotoxicity were examined. Methods: Linear and cyclic Carnosine 
peptide analogues were synthesized with appropriate protected amino acids and reagents 
using solid-phase peptide synthesis strategy, and anti-neoplastic activity of the 
synthesized compounds was examined on cancer cell lines of HepG2 (Human Liver 
Cancer Cell Line) and HT-29 (Human Colorectal Adenocarcinoma Cell Line) using MTT 
assay and flow cytometry analysis. Safety profile of the synthesized Carnosine analogues 
was also examined using skin fibroblast cells. Results: Our results showed that 
Carnosine analogues were toxic against HepG2 and HT-29 cell lines with a mean IC50 
value of 12.7 µg/mL. Flow cytometry analysis showed that such toxic activity could be, 
at least partly, through apoptosis induction. Conclusion: According to our experiments, 
in overall, compound 3b can be a good candidate for the further development of safe 
anticancer agents. On the other hand, the considerable toxicity of cyclic peptide 
analogues of Carnosine, 1c and 2c, on the cancerous cell lines along with their high 
safety profiles on the normal skin cells, make them attractive for further works on finding 
anticancer agents with peptide structure, giving better physicochemical properties for oral 
administration. 
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L-Carnosine, a natural dipeptide consisting of two 
amino acid residues, β-alanine and L-histidine, was 
discovered by Gulevich and Amiradzibi in 1900 from 
Liebig's meat extract [1]. The related compounds, such 
as anserine¬ (β-alanyl-3-methyl-L-histidine) and homo 
Carnosine ¬(γ-aminobutyryl-L-histidine) are also 
naturally occurring dipeptides, existing in skeletal 
muscles, heart, and brain of mammalian species, at high 
concentrations [ 2, 3]. 
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Many proposals have been made regarding the 
biological actions of Carnosine, including its role as a 
physiological intracellular buffer [4], a neurotransmitter 
[5], a metal chelator [6] and an antiglycating agent [7]. 
In addition, many biochemical studies have 
demonstrated that Carnosine possesses oxygen-free 
radical-scavenging and antioxidant properties [8-13]. 
Furthermore, an interesting observation with regard to 
the therapeutic value of Carnosine was made by 
Holliday and McFarland [14]. 
They demonstrated that Carnosine has an inhibitory 
effect on cultured neoplastic cells. In their study seven 
human cell lines and two rodent cell lines were used. 
Two of the human cell lines were derived from SV40-
transformed fibroblasts and the others were from 
cervical cancer, lung cancer, osteogenic sarcoma, 
bladder cancer, and prostate cancer [14]. Other studies 
showed that Carnosine inhibited tumor growth in 
animals [15, 16]. The molecular basis of the cytotoxic 
activity of Carnosine has not been known yet [17], 
however, some mechanisms have been suggested [18].  
In the present work, to shed further light on the 
understanding of the cytotoxic basis of Carnosine 
structure, we investigated the effect of Carnosine and 
Carnosine analogues, synthesized by solid phase peptide 
synthesis (SPPS) method, on some human cancerous 
cell lines, including HepG2 and HT-29 using MTT 
assay and flow cytometry analysis. Safety profiles of 
these peptides were also studied using normal skin 
fibroblast cells. Carnosine analogues designed and 
studied in this work were three linear and two cyclic 
peptides. 
2. Materials & Methods 
All Fmoc protected amino acids were purchased from 
Bachem, Switzerland. Reagents for peptide synthesis 
and solvents were bought from Merck Co, Germany. 
Resin was supplied from Santa Crus, USA. FT-IR 
spectra were recorded by a Nicolet Magna 550 Infra-
Red spectrometer, USA. Mass spectra were collected 
employing a 6410 Agilant LCMS triple Quadruple mass 
spectrometer with electrospray ionization interface, 
USA. NMR 1H spectra were obtained from a 300MHz 
Bruker Avance DRX Nuclear Magnetic Spectrometer, 
Germany. For MTT assay, absorbance was measured by 
a spectrophotometer plate reader (Infinite® M200, 
TECAN, Switzerland). DNA fragmentation analysis 
was performed by a FACSCalibur flow cytometry 
equipment (Becton Dickinson, CA, USA), supplied with 
the flowing software 2.5.1. 
Fluorescence measurement in lysosomal membrane 
integrity assay was implemented using a Shimadzu 
RF5000U fluorescence spectrophotometer, Japan. Cell 
lines were provided by Iranian Biological Resource 
Center, Tehran, Iran.  
2.1. Chemistry 
Detailed procedures for the synthesis of Carnosine and 
its peptide analogues were given in reference [19]. 
Briefly, 2- chlorotrityl chloride resin was employed to 
load fmoc amino acids, one by one, on the solid support 
using Fmoc strategy in peptide synthesis. 
Diisopropylethylamine (DIPEA) was used as a reagent 
for the first amino acid loading. CH3OH was then 
included in the reagents to cap remaining free 
tritylchloride groups of the resin. For all other amino 
acid attachments, O-(7-Azabenzotriazol-1-yl)-¬N,  ,   , 
  - tetramethyluronium hexafluorophosphate (HATU), 
as a coupling reagent, and DIPEA were applied. After 
each amino acid attachment, piperazine was used to 
deprotect the loaded amino acid/ peptide on the resin. 
For linear peptide synthesis, peptides were cleaved from 
the resin by concentrated trifluoroacetic acid (TFA) plus 
scavengers, precipitated in diethyl ether, and then 
collected. In the cyclic peptide synthesis, after loading 
peptides on the resin, partial cleavage was applied by 
TFA 1% to obtain protected peptides. Cyclization was 
carried out in a large amount of acetonitrile using 
DIPEA and PyBOP (Benzotriazol-1-yloxy) tri-
pyrrolidino-phosphonium hexafluorophosphate, as a 
coupling reagent. After cyclization, deprotected cyclic 
peptides were achieved by concentrated TFA containing 
scavengers. The peptides were then collected after 
precipitation in diethyl ether. Scheme 1 shows the 
whole procedure of the cyclopeptide synthesis of 
compound 1c. 
2.2. In vitro cytotoxic activity 
MTT assay and flow cytometry analysis were 
performed for all the synthesized peptides using HepG2 
(Human Liver Cancer) and HT-29 (Human Colorectal 
Adenocarcinoma) cell lines and skin fibroblast cells, as 
a control normal cell line,  with the same procedures as 
published in previous work [19]. 
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Scheme 1. The solid-phase synthesis of linear and cyclic Carnosine analogue 1c, cyclo(β-Ala-His-Pro-β-Ala-His) using 2- 
chlorotrityl chloride resin. 
 
2.3. Determination of lysosomal membrane integrity 
of HepG2 cells 
Lysosomal damage using acridine orange (AO), as a 
probe, was assayed following incubation of HepG2 cells 
with the peptides samples. Aliquots of the cell 
suspension (0.5 mL), previously incubated with the 
peptides samples (10 µg/mL), were stained with AO (5 
µM) and precipitated from the incubation medium by 1 
min centrifugation at 1000 rpm. The cell pellet was then 
suspended in 2 mL fresh incubation medium. This 
washing process was carried out twice to remove the 
fluorescent dye from the media. The AO redistribution 
in the cell suspension was then measured 
fluorimetrically using fluorescence spectrophotometer 
set at 495 nm excitation and 530 nm emission 
wavelengths. Lysosomal membrane damage was 
determined as difference in redistribution of acridine 
orange from lysosomes into cytosol between the treated 
cells and the control cells at the time of preparation 
[20]. 
2.4. Statistical analysis 
Graph Pad Prism 5 (Graph Pad Software, La Jolla, CA, 
USA) was used to analyze data by one way ANOVA, 
completed by Tukey’s post hoc test. All data were 
shown as arithmetic mean ± S.E.M of at least triplicate 
measurements. Data significance was assumed as 
P<0.05. 
 
3. Results and discussion 
The protected linear Carnosine analogues 
β-Ala-His(Trt)-β-Ala-His(Trt) (1a) 
Yield: 78%; Yellow oily liquid; IR (KBr):  (cm
-1
) 
3434.17 (NH), 2166.47 and 2555.28 (C=N in amino 
acid Histidine), 1664.92 (C=O amide), 1546.34 (C=C in 
amino acid Histidine), 600-800 (out-of-plane bending 
vibration C-H in amino acid Histidine); 
1
H NMR 
(CDCl3-d6, 300 MHz,): δ = 2.89-3.13 (m , CH2), 4.09-
5.03 (m, 2H, CH), 5.38-5.57 (m, CH2), 7.31-7.43 (m, 
12H, CH-Ar trityle of Histidine), 7.81-7.89 (t of t, 2H, 
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CH-Ar trityle of Histidine), 8.36-8.40 (d, 2H, NHCO); 
LC-MS (ESI) m/z Calcd for (1a) 918.434, Found m/z = 
917.90000[M-H]. 
β-Ala-His(Trt)-Pro-β-Ala-His(Trt) (2a) 
Yield: 75%; Yellow oily liquid; IR (KBr):  (cm
-1
) 
3428.45 (NH), 2167.10 and 2559.85 (C=N in amino 
acid Histidine), 1666.66 (C=O amide), 1546.62 (C=C in 
amino acid Histidine), 600-800 (out-of-plane bending 
vibration C-H in amino acid Histidine); 
1
H NMR 
(CDCl3-d6, 300 MHz,): δ = 3.38-3.42 (m, 15H, CH2), 
5.40-5.71 (s, br, 2H, NH2), 7.29-7.32 (s, br, CH=C 
Histidine), 7.39-7.42 (s, br, CH=N Histidine), 7.50-7.61 
(m, 24H, CH-Ar trityle of Histidine), 7.95-8.05 (t of t, 
2H, CH-Ar trityle of Histidine), 8.69-8.73 (d, 3H, 
NHCO); LC-MS (ESI) m/z Calcd for (2a) 1015.49, 
Found m/z = 1014.00000[M-H].   
 
Pro-β-Ala-His(Trt)-β-Ala-His(Trt) (3a) 
Yield: 75%; Yellow oily liquid; IR (KBr):  (cm
-1
) 
3451.30 (NH), 2164.07 and 2551.33 (C=N in amino 
acid Histidine), 1664.07 (C=O amide), 1545.98 (C=C in 
amino acid Histidine), 600-800 (out-of-plane bending 
vibration C-H in amino acid Histidine); 
1
H NMR 
(CDCl3-d6, 300 MHz,): δ = 3.24-3.29 (m, 15H, CH2), 
7.50-7.55 (m, 2H, CH=C Histidine), 7.55-7.60 (m, 2H, 
CH=N Histidine), 7.94-8.04 (t of t, 2H, CH-Ar trityle of 
Histidine), 8.28-8.40 (s, br, 24H CH-Ar trityle of 
Histidine), 8.56-8.69 (s, br, 4H, NHCO); LC-MS (ESI) 
m/z Calcd for (3a) 1015.49, Found m/z = 
1014.00000[M-H].   
 
β-Ala-His(Trt) (4a) 
Yield: 80%; Yellow oily liquid; IR (KBr):  (cm
-1
) 
3438.64 (NH), 2165.88 and 2556.05 (C=N in amino 
acid Histidine), 1664.42 (C=O amide), 1546.45 (C=C in 
amino acid Histidine), 600-800 (out-o-plane bending 
vibration C-H in amino acid Histidine); 
1
H NMR 
(CDCl3-d6, 300 MHz,): δ = 7.50-7.55 (m, 1H, CH=C 
Histidine), 7.55-7.60 (m, 1H, CH=N Histidine), 7.94-
8.04 (t of t, 1H, CH-Ar trityle of Histidine), 8.28-8.40 
(s, br, CH-Ar trityle of Histidine), 8.56-8.69 (s, br, 1H, 
NHCO); LC-MS (ESI) m/z Calcd for (4a) 468.228, 
Found m/z = 467.30000[M-H]. 
 




Yield: 78%; White solid; IR (KBr):  (cm
-1
) 3440.64 
(NH), 2163.68 and 2565.33 (C=N in amino acid 
Histidine), 1666.61 (C=O amide), 1546.72 (C=C in 
amino acid Histidine), 600-800 (out-of-plane bending 
vibration C-H in amino acid Histidine);
 1
H NMR 
(CDCl3-d6, 300 MHz,): δ =  2.54-2.60 (s, br, 4H, CH2-
CO β-alanine), 2.66-2.71 (s, br, 4H, CH2 Histidine and 
CH2-NH2 β-alanine), 3.11-3.22 (m, 2H, CH2 Histidine), 
3.42-3.47 (s, br, CH2-NH β-alanine), 6.33-6.56 (m, 1H, 
CH Histidine), 6.36-6.48 (t, 2H, NH2), 6.72-6.87 (m, 
1H, CH Histidine), 7.65-7.79 (t, 2H, CH=C Histidine), 
8.14-8.29 (t, 1H, NHCO), 8.51-8.71 (d, 2H, CH=N 
Histidine), 16.49-16.84 (s, 1H, NH imidazole cyclic 
Histidine); LC-MS (ESI) m/z Calcd for (1b) 434.215, 
Found m/z = 432.90000[M-H].  
 
β -Ala-His-Pro-β-Ala-His (2b) 
Yield: 75%; White solid; IR (KBr):  (cm
-1
) 3439.64 
(NH), 2164.39 and 2556.76 (C=N in amino acid 
Histidine), 1665.21 (C=O amide), 1546.14 (C=C in 
amino acid Histidine), 600-800 (out-of-plane bending 
vibration C-H in amino acid Histidine); 
1
H NMR 
(CDCl3-d6, 300 MHz,): δ = 0.88-0.96 (t, 2H, CH2 
proline), 3.18-3.27 (d of d, 1H, CH2 Histidine), 3.49-
3.53 (m, 1H, CH2 Histidine or s, 1H, NH Proline), 6.48-
6.59 (d of d, 2H, CH=C Histidine), 6.82-6.90 (t, 1H, 
CH-N Proline), 7.67-7.85 (t, 2H, CH Histidine), 8.18-
8.32 (t, 1H, NHCO), 8.57-8.79 (d, 2H, CH=N 
Histidine), 16.67-16.77 (s, 1H, NH imidazole cyclic 
Histidine),
 13
C NMR (CDCl3-d6,75 MHz,)   = 115.25, 
119.20 (C=C Histidine), 126.98, 129.26 (C-Histidine), 
141.65, 145.44 (C=N), 156.97, 161.29, 161.77, 162.24 
(C=O), 170.64 (COOH); LC-MS (ESI) m/z Calcd for 
(2b) 531.268, Found m/z = 529.90000[M-H]. 
Pro-β-Ala-His-β-Ala-His (3b) 
Yield: 75%; White solid; IR (KBr):  (cm
-1
) 3438.64 
(NH), 2165.77 and 2569.91 (C=N in amino acid 
Histidine), 1666.21 (C=O amide), 1546.57 (C=C in 
amino acid Histidine), 600-800 (out-of-plane bending 
vibration C-H in amino acid Histidine); 
1
H NMR 
(CDCl3-d6, 300 MHz,): δ = 1.07-1.13 (t, 2H, CH2 
proline), 1.15-1.19 (m, 2H, CH2 proline), 1.87-2.03 (s, 
br, 1H, NH proline), 2.72-2.81 (m, 1H, CH2 Histidine), 
2.82-2.92 (m, 1H, CH2 Histidine), 3.34-3.44 (d of d 
simillar q, J=7.02 Hz, CH-NH proline), 3.63-3.74 (m, 
1H, CH2 of each Histidine), 6.65-6.75 (m, 1H, CH 
Histidine), 7-7.08 (m, 1H, CH Histidine), 7.71-7.92 (t, 
2H, CH=C Histidine), 8.22-8.40 (t, 1H, NHCO), 8.69-
8.89 (d, 2H, CH=N Histidine), 17.37-17.55 (s, 1H, NH 
imidazole cyclic Histidine); LC-MS (ESI) m/z Calcd for 
(3b) 531.268, Found m/z = 529.90000[M-H].   
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β-Ala-His (Carnosine) (4b) 
Yield: 80%; White solid; IR (KBr):  (cm
-1
) 3438.64 
(NH), 2164.07 and 2561.28 (C=N in amino acid 
Histidine), 1666.62 (C=O amide), 1547.02 (C=C in 
amino acid Histidine), 600-800 (out-of-plane bending 
vibration C-H in amino acid Histidine);
 1
H NMR 
(CDCl3-d6, 300 MHz,): δ = 7.80-7.89 (t, 1H, CH=C 
Histidine), 8.28-8.37 (t, 1H,  H β-alanine), 8.77-8.85 
(d, 1H, CH=N Histidine), 17.51-17.64 (s, 1H, NH 
imidazole cyclic Histidine),
 13
C NMR (CDCl3-d6,75 
MHz,)   = 115.41 (C=C Histidine), 129.38 (C-
Histidine), 144.52 (C=N), 162.48 (C=O), 174.39 
(COOH); LC-MS (ESI) m/z Calcd for (4b) 226.119, 
Found m/z = 224.90000[M-H].   
 
The deprotected cyclic Carnosine analogues 
Cyclo(β-Ala-His-Pro-β-Ala-His) (1c) 
Yield: 75%; Yellow solid; IR (KBr):  (cm
-1
) 3438.45 
(NH), 1673.24 (C=O amide), 1537.69 (C=C in amino 
acid Histidine), 600-800 (out-of-plane bending vibration 
C-H in amino acid Histidine); 
1
H NMR (CDCl3-d6, 300 
MHz,): δ = 4.01-4.22 (m, 1H, CH-N proline), 4.35-4.48 
(m, 1H, CH-NH Histidine), 4.79-4.84 (m, 1H, CH-NH 
Histidine), 6.81-6.88 (d, 2H, CH=C Histidine), 7.13-
7.21 (t, 1H,  H β-alanine), 8.26-8.33 (d, 1H, NH 
Histidine), 8.42-8.51  
(t, 1H,  H β-alanine), 8.89-9.16 (m, 2H, CH=N 
Histidine); LC-MS (ESI) m/z Calcd for (1c) 513.268, 




Yield: 75%; Yellow solid; IR (KBr):  (cm
-1
) 3415.11 
(NH), 1673.93 (C=O amide), 1544.00 (C=C in amino 
acid Histidine), 600-800 (out-of-plane bending vibration 
C-H in amino acid Histidine); 
1
H NMR (CDCl3-d6, 300 
MHz,): δ = 2.39-2.56 (m, 1H, CH2 Histidine or CH2 
proline), 2.60-2.74 (m, 1H, CH2 Histidine or CH2 
proline), 2.95-3.21 (m, 1H, CH2 Histidine), 3.38-3.43 
(m, 2H, CH2-N proline), 3.46-3.70 (m, 1H, CH2 
Histidine), 3.97-4.11 (m, 1H, CH-NH Histidine), 4.27-
4.43  (m, 1H, CH-NH Histidine), 4.68-4.72 (m, 1H, CH 
proline), 7.43-7.54 (d of d, 2H, CH=C Histidine), 8.03-
8.14 (t, 1H,  H β-alanine), 8.68-8.77 (d, 2H, CH=N 
Histidine), 8.91-9 (d, 1H, NH Histidine); LC-MS (ESI) 




MTT assay results 
Table 1 shows the IC50 results of HepG2 and HT-29 
cancer cell lines, affected by the linear and cyclic 
peptide analogues of Carnosine (values ranging from 
9.18 to 16.23 µg/mL).  IC50 results for 5-flurouracil, as a 
standard toxic drug, are given for comparison. Table 2 
contains viability percentage data for the three cell lines; 
skin fibrobast, HepG2, and HT-29 cancer cells. 
 
Table 1. IC50 values (μg/mL) for toxicity of the peptides on HepG2 and HT-29 cells in MTT assay. Values are presented from the corresponding 
control (*P <0.05, *** P <0.001). 
Entry IC50 Cell line HepG2 IC50 Cell line HT-29 
1b 9.5 ± 0.1583 
***
 10.73 ± 0.0014 
***
 
2b 9.33 ± 0.0919 
*
 10.11 ± 0.0028 
***
 
3b 10.21 ± 0 14.23 ± 0.0035 
***
 
4b (Carnosine) 10.01 ± 0.0063 
***
 16.23 ± 0.0021 
***
 
1c 9.18 ± 0.17 
***
 9.64 ± 0.11 
***
 
2c 9.21 ± 0.42 
***
 10.53 ± 0.11 
***
 
5-Fluorouracil (Standard drug) 3.16 6.08 
 
Table 2. Validity percentage of the cell lines of skin fibroblast, HepG2 and HT-29 exposed to the linear and cyclic Carnosine analogues, in MTT 
assay 
Entry Viability percentage (Fibroblast) Viability percentage (HepG2) 
Viability percentage 
(HT-29) 
1b 70.93 83.8 13.81 
2b 95.25 99.04 27.63 
3b 70.72 3.28 13.97 
4b 94.98 8.01 27.79 
1c 75.39 9.2 11.76 
2c 78.87 19.31 12.44 
5-FU 8.64 3.22 9.28 
control 100 100 100 
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Viability percentage (HepG2) 
Viability percentage 
(HT-29) 
1b 84.56 89.63 12 0.67 
2b 89.18 90.21 0.43 0.33 
3b 99.68 67.52 0.33 32.43 
4b 86.69 84.65 7.86 0.42 
1c 99.46 99.82 0.55 0.18 




Figure1. Flow cytometry results obtained from the peptide-treated HepG2 and HT-29 cells. The left: Dot plots show the relative size of the cells, in the 
horizontal axis by the forward scatter (FSC) parameter and the vertical axis demonstrates the granularity of the cells by side scatter (SSC) parameter. The right:  
Histograms show the fluorescence intensity of the peptide-treated cells in the FL-2 channel scaled on the PI emission wavelength [22]. 
 
Flow cytometry analysis results 
Table 3 represents flow cytometry results for Carnosine 
and its linear and cyclic peptides analogues. All the 
histograms achieved are included in the supplementary 
file. Fig.1 shows only the histogram of 3b as an example 
[21]. 
 
Lysosomal membrane integrity results  
Lysosomal damage was assayed using acridine orange, 
as a probe, through the peptide-treated HepG2 cells. 
Values are presented as mean ± SD of three independent 
experiments, performed for determination of lysosomal 
membrane integrity of HepG2 cells (Fig 2). As shown in 
Fig 2, linear peptide 1b caused the highest absorption of 
acridine orange dye in the cells. 
 
Figure 2. Determination of lysosomal membrane integrity assay on 
HepG2 cells. The values show acridine orange absorbance of the 
damaged lysosomes of the peptide-treated HepG2 cells and are 
presented as mean ± SD of three independent experiments (n= 3). The 
stars show the values, which are significantly different from the 
corresponding control (**P <0.01, *** P <0.001). 
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4. Discussion 
The synthesized linear and cyclic Carnosine analogues 
demonstrated cytotoxic activity on the cells of HepG2 
(Human Liver Cancer Cell Line) and HT-29 (Human 
Colorectal Adenocarcinoma Cell Line) with IC50 values 
in the range of 9.18 to 16.23      . 5-Fluorouracil (5-
FU) was employed as a standard cytotoxic drug in MTT 
assay. Among the peptides, compounds 1b and 2b 
showed a high viability percentage (low toxicity) on the 
liver cancerous cell line of HepG2, whereas these and 
other synthesized compounds presented a low viability 
percentage (high toxicity) on the colon cancerous cell 
line of HT-29 (see Table 2). In addition, compounds 3b, 
1c, and 2c showed high toxicity effects (low viability 
percentages) on the both cell lines of HepG2 and HT-
29, comparable with Carnosine (compound 4b). In this 
regard, the peptides 3b and 1c were the most effective 
cytotoxic agents. Moreover, compound 3b showed 
toxicity on HepG-2 cells as high as 5-Fu did. Table 3 
and Fig.1 show the results, obtained from flow 
cytometry analysis of the peptides-treated cancerous cell 
lines. The signals, obtained in H-1 area, mean that 
propidium iodide (PI) was able to enter the cells, bind to 
DNA, and lead to apoptosis, whereas the signals, 
appeared in H-2 area, indicate that the cancerous cells, 
treated with peptides, remained intact (20). According 
to Table 3, all the synthesized peptides could induce 
apoptosis on the cancerous cell lines. The peptides 3b 
and 1c showed pronounced toxic effects on the 
cancerous cell line of HepG2 compared with the other 
peptides, which can be attributed to better cell 
permeability of the synthesized peptides on HepG2 
cells. In this view, HT-29 cells were more resilient 
towards these peptides. As our results showed, it was 
also true for 5-FU. In overall, among the synthesized 
peptides, compound 3b gave the highest cytotoxic 
activity on HepG2, similar to 5-FU.  Moreover, 
compound 3b showed a much higher safety profile on 
skin normal cells compared to 5-FU. Our results also 
indicated that Carnosine dimers with a proline amino 
acid, connected with the two monomers, give 
compounds with a profound variation in their anticancer 
activities on cancerous cells. This result is in accordance 
with our previous study on the synthesized inverse 
Carnosine peptide analogues [19]. 
In this work, MTT results for compounds 1b and 2b 
were not consistent with apoptosis of HepG-2 cells, 
found using flow cytometry analysis, whereas for the 
other peptide analogues, the MTT results were in 
agreement with the data of flow cytometry assay. In 
order to find cytotoxic activity mechanism of the linear 
peptides 1b and 2b, lysosomal membrane integrity 
experiment was employed. As shown in Fig. 2, HepG-2 
cells absorbed more acridine orange dye after exposure 
to the peptide 1b than the other peptides compared with 
the untreated cells (the control group). This means that 
lysosomes of HepG-2 cells were more damaged, and 
thus resulted in more release of cathepsin, which in turn, 
by binding to acridine orange gave higher absorption 
intensity, detected by the instrument. The more release 
of cathepsin means that more apoptosis has occurred 
[23]. Therefore, the results of lysosomal membrane 
integrity experiment suggest that the mechanism of 
apoptotic action of the linear peptide 1b is mediated 
through the lysosomal damage more than the 
mitochondrial pathway. For compound 2b, the 
mechanism of cytotoxicity remained to be determined. 
5. Conclusion 
Cytotoxic effect was observed for the linear and cyclic 
Carnosine peptide analogues on HepG2 and Ht-29 cell 
lines with varying amounts. In MTT assay, compounds 
3b and 1c caused low viability of the both cell lines. 
Moreover, compound 3b showed the lowest cell 
viability result (i.e., the highest cytotoxic activity) for 
the cell line HepG2 and this activity was similar to that 
of 5-Fu on this cell line. In addition, compound 3b 
showed a much higher safety profile on skin normal 
cells compared to 5-FU did. Our results also indicated 
that Carnosine dimers with a proline amino acid, 
connected with the two monomers, could give 
compounds with a profound variation in their anticancer 
activities on cancerous cells. 
According to our experiments, in overall, compound 3b 
can be a good candidate for the further development of 
safe anticancer agents. On the other hand, the 
considerable toxicity of cyclic peptide analogues of 
Carnosine, 1c and 2c, on the cancerous cell lines along 
with their high safety profiles on the normal skin cells, 
make them attractive for further works on finding 
anticancer agents with peptide structure, giving better 
physicochemical properties for oral administration. 
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